Caitlin Mollison, Managing Editor

In the third part of the series, we further explore the factors that contribute to overall happiness in a position.

A total of 150 respondents rated their satisfaction with total annual compensation as 4.15 on a scale of 1 to 7, down from 4.41 in 2021.

Findings from the University of British Columbia’s Life Sciences Institute show a potential path toward antiviral treatments that could be used against many different pathogens.

Long-term data showed no difference in the clinical benefit between the treatments for HER2-negative early breast cancer with homologous recombination deficiency.

The phase 3 clinical trial shows that the 5-year OS for patients with HR+/HER2- advanced breast cancer in the abemaciclib plus fulvestrant group was 41.2% vs 29.2% for the placebo arm.

Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.

BYLieve clinical trial data indicate long-term and very-long-term data disease control was observed in 25.6% and 16.5% of patients, respectively, with PFS at 24.8 and 29.4 months in patients with HR-positive, HER2-negative advanced breast cancer.

Efficacy and safety profile in combination with alpelisib is comparable to that reported in the BYLieve and SOLAR-1 clinical trials, according to a poster presentation at the San Antonio Breast Cancer Symposium.

Clinical trial results found that second-line treatment with trastuzumab deruxtecan led to significantly longer overall survival compared with trastuzumab emtansine.

DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.

Tumor microenvironment differences in Black women may explain disparities in outcomes for those with residual tumors after chemotherapy treatment for ER–positive/HER2-negative breast cancer.

Breast cancer expert joined a panel to discuss aromatase inhibitors at the San Antonio Breast Cancer Symposium (SABCS) on December 6, 2022.

Phase 3 monarchE trial assesses distant relapse free-survival, invasive disease-free survival, and overall survival for the treatment of HR-positive/HER2-negative-, node-positive, high-risk early breast cancer.

RxPonder clinical trial results indicate that racial disparities continue to be a major health care challenge.

Results of RIGHT Choice phase 2 clinical trial show Kisqali doubled PFS and showed fewer adverse events.

Pharmacy Times® will be onsite in Texas providing written and video content for the SABCS, which takes place December 6 to 10.

Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.

A presentation at the AMCP Nexus conference focuses on the health care disparities and pharmacotherapy options for gender affirmation.

Presentation at the AMCP Nexus conference focuses on midterm election outlook and a plug for the Pre-approval Information Exchange Act.

Keynote speaker at the AMCP Nexus conference discusses recent FDA approvals and those scheduled over the next year.

Panelists at the AMCP Nexus conference share tips on new opportunities for students and career-changers looking to forge a new path.

Panelists at the AMCP Nexus conference discuss the burden of undertreated and untreated chronic kidney disease.

Experts discuss the clinical and economic impact of misdiagnosing bipolar I disorder as major depressive disorder.

The Academy of Managed Care Pharmacy kicks off AMCP Nexus 2022 with a wide variety of educational sessions and policy discussions.

Three-year follow-up analysis shows that Gilead’s car T-cell therapy induced high rates of durable response and a median overall survival of 46.6 months.

AstraZeneca trial results shows 90% of patients with chronic lymphocytic leukemia surviving for 5 years.

Genentech has released new 2-year data for individuals with diabetic macular edema and wet age-related macular degeneration.

Pharmacy Moms Group special task force develops guidelines as precautions are implemented amid the COVID-19 pandemic.

As the COVID-19 pandemic continues, a key issue for pharmacists, other health care professionals, and patients is the potential for disruptions in the US medication supply chain.

Care planning can increase pharmacy profits through efficiencies and through new revenue from payers that value what pharmacists do for patients, if they see the documentation of what has been done.